4//SEC Filing
Menzaghi Frederique Ph.D. 4
Accession 0001209191-22-013986
CIK 0001346830other
Filed
Feb 28, 7:00 PM ET
Accepted
Mar 1, 4:16 PM ET
Size
9.7 KB
Accession
0001209191-22-013986
Insider Transaction Report
Form 4
Menzaghi Frederique Ph.D.
VP-Research & Development
Transactions
- Sale
Common Stock
2022-02-25$10.29/sh−2,114$21,753→ 171,565 total - Award
Common Stock
2022-02-25+20,000→ 173,679 total - Award
Employee Stock Option (Right to Buy)
2022-02-25+40,000→ 40,000 totalExercise: $10.46Exp: 2032-02-25→ Common Stock (40,000 underlying)
Footnotes (3)
- [F1]Represents the number of shares underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in three equal annual installments on each of February 25, 2023, February 25, 2024 and February 25, 2025, in each case, subject to the Reporting Person's continued service (as that term is defined in the Issuer's 2014 Equity Incentive Plan) as of each such date.
- [F2]This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting of RSUs reported in the Form 4 filed with the Securities and Exchange Commission on August 26, 2021, and does not represent a discretionary trade by the Reporting Person.
- [F3]The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on March 25, 2022, in each case subject to the Reporting Person's continued service as of each such date.
Documents
Issuer
Cara Therapeutics, Inc.
CIK 0001346830
Entity typeother
Related Parties
1- filerCIK 0001597152
Filing Metadata
- Form type
- 4
- Filed
- Feb 28, 7:00 PM ET
- Accepted
- Mar 1, 4:16 PM ET
- Size
- 9.7 KB